Becoming a strong regional player and the first partnering choice
Expanding the product portfolio will strenghten the growth potential.
Grow organically in selected new markets to become a strong regional player with stable, geographically diversified revenues by:
Maintain the Company’s position as a leading Bulgarian pharmaceutical manufacturer with high quality affordable products and improve existing products.
Two new medicinal products have been authorised:- Diclofenac Diethylamine 23.2 mg/g gel (DCP - Denmark, Sweden, Norway, Finland);License:- Paracedol Duo 200 mg/ 500 mg fct (Bulgaria).
Further consolidate and integrate the Group to optimize its cost structure, control entirely the production chain and benefit from potential synergies.